Nephro Care India Reports 90% Rise in H2FY25 Net Profit

Deepak Parekh-backed multi-specialty healthcare provider, Nephro Care India Limited (NCIL) has posted a 90.10 per cent growth in standalone net profit of Rs 1.45 crore for the second half (H2) ended March 31, 2025, as compared with Rs 76 lakh same period last year.

Operating income on a standalone basis more than doubled at Rs 28.34 crore during H2FY25, as against Rs 14.13 crore same period last year.

For the year ended March 31, 2025, the company’s operating income on standalone basis grew by 69.04 per cent at Rs 46.03 crore as against Rs 27.23 crore last year. However, net profit decreased by 17.51 per cent at Rs 3.64 crore, as compared with Rs 4.41 crore in 2023-24 on account of higher staff cost for the multispecialty hospital Vivacity at Madhyamgram in Kolkata. Employee benefit expenses increased by 251.38 per cent at Rs 7.59 crore during 2024-25, as compared with Rs 2.16 crore last year.  

The company’s operating profit (EBITDA) surged nearly 8.24 per cent to Rs 7.40 crore during FY25 as against Rs 6.84 crore during FY24. It reported an EBITDA margin of 16.08% in FY 25 as compared to 25.10% in FY24 on account of the increased staff cost. 

Commenting on the performance of the company during H2FY25, Dr Pratim Sengupta, Founder, MD & CEO, Nephro Care India, said, “We have witnessed a good growth in topline in H2FY25 backed by our efforts to expand our network to make renal care accessible and affordable to masses. India lacks adequate infrastructure to provide specialized renal care and this leads to high burden of end-stage kidney disease. It is our endeavour to help bridge the existing demand supply gap by setting up advanced renal care clinics across the country so as to make quality kidney care accessible to people in the remote corners of the country. We plan to set up 22 renal care clinics by March 2026. However, our net profit and EBITDA margin has been slightly under pressure during FY25 on account of the higher expenses toward staff cost for the newly set up hospital. But Vivacity is now fully operational and we expect that to further contribute to the growth in our topline and bottomline moving forward.”

NCIL offers a wide range of clinical and lifestyle solutions and renal insufficiency treatment to patients with the treatment framework covering the entire range of lifestyle, physiological and spiritual aspects of wellness.

With a view to make renal care more “accessible and affordable” to masses, the company is developing a prototype of remotely monitored AI-enabled Smart Haemodialysis Machine in collaboration with the National Institute of Technology, Silchar. Once ready, it is likely to bring down the cost of these machines by nearly 70-75 per cent to Rs 2 lakh from the current Rs 7.5-8 lakh.